{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T15:54:56Z","timestamp":1761580496252},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.eururo.2007.03.078","type":"journal-article","created":{"date-parts":[[2007,4,6]],"date-time":"2007-04-06T15:34:53Z","timestamp":1175873693000},"page":"1115-1122","source":"Crossref","is-referenced-by-count":33,"title":["Weekly Paclitaxel and Carboplatin against Advanced Transitional Cell Cancer after Failure of a Platinum-Based Regimen"],"prefix":"10.1016","volume":"52","author":[{"given":"Tsutomu","family":"Kouno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikako","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Katsumata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motokiyo","family":"Komiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eijiro","family":"Okajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2007.03.078_bib1","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2007.03.078_bib2","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2007.03.078_bib3","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.1994.12.11.2264","article-title":"Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group","volume":"12","author":"Roth","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2007.03.078_bib4","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.2002.20.4.937","article-title":"Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer","volume":"20","author":"Vaughn","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2007.03.078_bib5","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/S0022-5347(01)66765-X","article-title":"Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies","volume":"154","author":"Tu","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.03.078_bib6","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1200\/JCO.2002.11.114","article-title":"Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma","volume":"20","author":"Pagliaro","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2007.03.078_bib7","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0022-5347(17)39672-6","article-title":"Randomized phase II evaluation of carboplatin and CHIP in advanced transitional cell carcinoma of the urothelium. The Eastern Cooperative Oncology Group","volume":"144","author":"Trump","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.03.078_bib8","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/(SICI)1097-0142(19971115)80:10<1966::AID-CNCR14>3.0.CO;2-W","article-title":"Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma","volume":"80","author":"Bellmunt","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2007.03.078_bib9","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/cncr.20123","article-title":"Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium","volume":"100","author":"Dreicer","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2007.03.078_bib10","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1002\/(SICI)1097-0142(19991115)86:10<2066::AID-CNCR26>3.0.CO;2-1","article-title":"Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro","volume":"86","author":"Engblom","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2007.03.078_bib11","first-page":"6s","article-title":"Phase III study of weekly paclitaxel via 1-hour infusion versus standard 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC","volume":"22","author":"Seidman","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.eururo.2007.03.078_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1006\/gyno.2002.6859","article-title":"Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer","volume":"88","author":"Havrilesky","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.eururo.2007.03.078_bib13","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1200\/JCO.2003.02.563","article-title":"Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation","volume":"21","author":"Belani","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2007.03.078_bib14","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1200\/JCO.2002.08.129","article-title":"Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer","volume":"20","author":"Loesch","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2007.03.078_bib15","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1081\/CNV-200029064","article-title":"A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer","volume":"22","author":"Friedland","year":"2004","journal-title":"Cancer Invest"},{"key":"10.1016\/j.eururo.2007.03.078_bib16","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/oxfordjournals.annonc.a058668","article-title":"Second-line M-VAC therapy in patients previously treated with the M-VAC regimen for metastatic urothelial cancer","volume":"4","author":"Kattan","year":"1993","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2007.03.078_bib17","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0959-8049(98)00030-6","article-title":"A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer","volume":"34","author":"Lorusso","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2007.03.078_bib18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/(SICI)1097-0142(19990801)86:3<514::AID-CNCR21>3.0.CO;2-9","article-title":"A phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium","volume":"86","author":"Sweeney","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2007.03.078_bib19","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1200\/JCO.2005.03.6699","article-title":"Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium","volume":"24","author":"Sweeney","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2007.03.078_bib20","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/sj.bjc.6603118","article-title":"A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen","volume":"94","author":"Culine","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2007.03.078_bib21","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/cncr.21370","article-title":"Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study","volume":"104","author":"Vaishampayan","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2007.03.078_bib22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.1997.15.2.589","article-title":"Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma","volume":"15","author":"Witte","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2007.03.078_bib23","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1200\/JCO.1997.15.5.1853","article-title":"Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma","volume":"15","author":"McCaffrey","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2007.03.078_bib24","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/jnci\/83.4.285","article-title":"Fluorouracil and recombinant human interferon alfa-2a in the treatment of metastatic chemotherapy-refractory urothelial tumors","volume":"83","author":"Logothetis","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2007.03.078_bib25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3109\/07357909509094462","article-title":"Phase II trial of ifosfamide, fluorouracil, and folinic acid (FIFO regimen) in relapsed and refractory urothelial cancer","volume":"13","author":"Kattan","year":"1995","journal-title":"Cancer Invest"},{"key":"10.1016\/j.eururo.2007.03.078_bib26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/(SICI)1097-0142(19970801)80:3<465::AID-CNCR14>3.0.CO;2-V","article-title":"Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1): a clinical phase II study","volume":"80","author":"Otto","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2007.03.078_bib27","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1023\/A:1026589120989","article-title":"Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-alpha as second-line treatment of advanced transitional cell cancer of the urothelial tract","volume":"11","author":"De Mulder","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2007.03.078_bib28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005392-200101000-00017","article-title":"Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study","volume":"165","author":"Krege","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2007.03.078_bib29","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/jjco\/hyh132","article-title":"FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder","volume":"34","author":"Di Lorenzo","year":"2004","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.eururo.2007.03.078_bib30","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s00280-005-0175-4","article-title":"Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy","volume":"58","author":"Shinohara","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.eururo.2007.03.078_bib31","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1182\/blood.V97.3.638","article-title":"Investigating the platelet-sparing mechanism of paclitaxel\/carboplatin combination chemotherapy","volume":"97","author":"Pertusini","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.eururo.2007.03.078_bib32","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.eururo.2005.04.035","article-title":"Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer","volume":"48","author":"Johannsen","year":"2005","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283807004575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283807004575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T11:20:39Z","timestamp":1546946439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283807004575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0302283807004575"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2007.03.078","relation":{},"ISSN":["0302-2838"],"issn-type":[{"type":"print","value":"0302-2838"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}